People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Other Health Care, Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alumis Inc. | — | Biotechnology | Series D+ | $240.0M | $432.7M | 2021 |
| Fulcrum Therapeutics, Inc. | — | Biotechnology | Series C | $183.2M | $2.8B | 2018 |
| Wavetec Vision Systems Inc | — | Other Health Care | Series B | $99.9M | $64.1M | 2013 |
| Interline Therapeutics, Inc. | — | Pharma | Series C | $92.6M | $1.1B | 2021 |
| Tarsa Therapeutics, Inc. | — | Biotechnology | Series B | $46.8M | $21.8M | 2012 |
| Vitae Pharmaceuticals, Inc | — | Pharmaceuticals | Series A | $15.0M | $464.6M | 2009 |
James Tananbaum at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Tananbaum on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Vikram Bajaj | 2 | 3 |
| Bryan Roberts | 1 | 18 |
| Peter Barrett | 1 | 18 |
| Bruce Feuchter | 1 | 12 |
| Srinivas Akkaraju | 1 | 10 |
| Mark Levin | 1 | 9 |
| James Collins | 1 | 8 |
| Alan Colowick | 1 | 7 |
| Eric Bednarski | 1 | 7 |
| Richard Gaster | 1 | 7 |
| Lewis Geffen | 1 | 6 |
| Anthony Lando | 1 | 6 |
| Gerard Van Hamel Platerink | 1 | 6 |
| Bryant Fong | 1 | 5 |
| Charles Warden | 1 | 5 |
| Joe Mandato | 1 | 5 |
| Scott Cooper | 1 | 5 |
| Martin Edwards | 1 | 5 |
| Richard Levy | 1 | 4 |
| Ashleigh Palmer | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.